Linagliptin (Trajenta ) Type 2 Diabetes Drug Now Approved in Europe

By Mike on August 26, 2011 in Diabetes News, Featured

Linagliptin, is currently being sold in the United States under the trade name Tradjenta and it now has European approval.

Indianapolis-based Lilly and Boehringer, a German company, said the European Commission granted marketing authorization for 5-milligram tablets to be used alone or in combination with other treatments.

Lilly and Boehringer entered an agreement earlier this year to develop and sell up to five drugs, and Tradjenta is the first of those products. In May, the U.S. Food and Drug Administration approved it to be used as a stand-alone treatment or in combination with other diabetes drugs.

Enrique Conterno, president of Lilly Diabetes, said: “The EU approval of linagliptin marks another major regulatory milestone for the Boehringer Ingelheim and Lilly alliance in diabetes. “Linagliptin can be an important treatment option for adults living with type II diabetes,” he added

As yet, as with most other drugs that come on to the market, Spain will usually take a while to market this product.

Pin It

Buffer